Accretion Pharmaceuticals Limited
Bookbuilding IPO · NSE
- Price band
- ₹101 - ₹101
- Lot size
- 1,200 shares
- Issue amount
- ₹29.75 cr
- Total subscription
- 7.32×
- Opens
- 14 May 2025
- Closes
- 16 May 2025
- Allotment
- 19 May 2025
- Listing
- 21 May 2025
Offer at a glance
Issue overview
- Issue size
- 29,46,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,21,200
- Fresh issue
- ₹29.75 cr
- Offer for sale
- ₹0 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- NSE
- Maximum investment
- ₹1,21,200
- Issue type
- Bookbuilding IPO
- Shares before issue
- 81,70,000
- Shares after issue
- 1,11,16,000
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 1,200 | ₹1,21,200 |
| HNI | 2 | 2,400 | ₹2,42,400 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | — | 4 |
| NIB | — | 889 |
| RETAIL | — | 10,746 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 1.43 | 17.37 |
| RETAIL | 12.35 | 130.24 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Dec-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 8.74 | 9.69 | 0.26 |
| ROE | 38.54 | 72.47 | 2.7 |
| ROCE | 30.14 | 36.73 | 9.87 |
| RONW | 38.54 | 72.47 | 2.7 |
| PRE IPO(PE) | 0 | 21.29 | 0 |
| POST IPO(PE) | 16.08 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Accretion Pharmaceuticals Limited, founded in 2012 and based in Ahmedabad-Sanand, Gujarat, is a pharmaceutical company active in formulations and contract manufacturing with 83 employees as of January 2025. The company offers a wide range of products including tablets, capsules, syrups, ointments, creams, medicated shampoos, dusting powders, and ayurvedic wellness products, and also provides third-party manufacturing services. The proposed fund usage mainly focuses on growth capex such as facility upgrades and new machinery to increase capacity and support exports to 20+ countries, along with working capital needs, limited debt repayment, and flexibility for general purposes, helping the company scale operations, maintain quality standards, improve liquidity, and support future expansion opportunities.
Strengths
- Experienced Leadership: Run by promoters and management with strong industry expertise.
- Strong Relationships: Long-standing client & supplier partnerships support business stability.
- Quality Focus: ISO-certified systems ensure high-quality pharmaceutical & healthcare products.
Risk factors
- Ongoing Legal Cases: Current court proceedings could harm the company’s reputation and business performance.
- Changing Regulations: Not keeping up with updated pharmaceutical laws may lead to disruptions and affect business operations.
- Regulatory Checks: Unfavorable inspection results from authorities or clients could lead to penalties or damage the company’s image.
Promoters
Mr. Mayur Popatlal Sojitra
Mr. Harshad Nanubhai Rathod
Mr. Vivek Ashok Kumar Patel
Mr. Hardik Mukundbhai Prajapati.
Registrar & documents
Lead manager
Jawa Capital Services Private Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗Check allotment status on registrar →Registered office
29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvad Sanand
+91-97148 82929
[email protected]Company website ↗Frequently Asked Questions
What is Accretion Pharmaceuticals IPO GMP today?
Currently, Accretion Pharmaceuticals IPO Grey Market Premium (GMP) is trading around ₹0 or awaiting active buyer-seller quotes in the grey market. The issue price is set at ₹101. Track daily updates on IPO Premiums as bidding numbers unfold.
What is the lot size and minimum investment for Accretion Pharmaceuticals IPO?
The minimum bid lot size for Accretion Pharmaceuticals IPO is 1,200 shares. At the cut-off price of ₹101 per share, retail investors need a minimum application amount of ₹1,21,200 per lot. Retail applicants can apply for a maximum of 1 lots (up to ₹2,00,000).
When will Accretion Pharmaceuticals IPO allotment status be announced?
The allotment status for Accretion Pharmaceuticals IPO is scheduled to be finalized on 19 May 2025. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Kfin Technologies Limited's official portal or via BSE/NSE allotment portals.
How can I check Accretion Pharmaceuticals IPO allotment status online by PAN?
To check Accretion Pharmaceuticals IPO allotment status: 1) Visit the registrar portal (Kfin Technologies Limited) or the BSE IPO allotment page. 2) Select 'Accretion Pharmaceuticals Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Explore More IPO Analysis & Live Tools
Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.